February 12, 2026 – QuidelOrtho Company publicizes monetary outcomes for the fourth quarter and full yr ended December 28, 2025.

“In 2025, we transitioned from COVID-induced volatility to a extra sustainable, diversified diagnostics firm,” mentioned Brian J. Blaser, President and Chief Government Officer of QuidelOrtho. “Our Labs, Immunohematology and Cardiac companies delivered constant development, whereas value financial savings initiatives delivered significant margin enlargement. In consequence, we’re properly positioned to generate materially stronger free money circulation in 2026, which we imagine higher displays our firm’s earnings energy.”

Key outcomes fourth quarter 2025:
(all comparisons are with the earlier yr interval)

• Complete income was $724 million, as reported
  • Non-respiratory revenues of $600 million; excluding donor screening¹non-respiratory gross sales grew by 7% at fixed trade charges.
    • Labs income grew 8% as reported and seven% at fixed trade charges.
  • Respiratory revenues have been reported at $123 million, down 14% attributable to decrease COVID-19 testing.
    • Flu revenues rose 6%, each as reported and at fixed trade charges.
• GAAP working money circulation was $132 million; free money circulation² amounted to $87 million.
• GAAP internet loss was $131 million; GAAP working loss was $66 million; the underlying enterprise delivered adjusted EBITDA of $153 million.
• GAAP internet loss margin was (18)%; GAAP working margin was (9)%; the adjusted EBITDA margin was 21%.
• GAAP diluted loss per share was $1.92; adjusted diluted earnings per share (“EPS”) was $0.46.

Key outcomes for the complete yr 2025:
(all comparisons are with the earlier yr)

• Complete income, as reported, was $2.73 billion
  • Non-respiratory revenues of $2.33 billion; excluding donor screening¹non-respiratory gross sales grew by 5% at fixed trade charges.
    • Labs income grew 6%, each as reported and at fixed trade charges.
  • Respiratory revenues have been reported at $402 million, which fell 20% attributable to decrease COVID-19 testing.
    • Flu revenues elevated 3%, each as reported and at fixed trade charges.
• GAAP working bills³ and non-GAAP working bills each declined 5%, pushed by the corporate’s value financial savings initiatives.
• GAAP working money circulation was $105 million; free money circulation² of $(77) million consists of one-time investments within the firm’s ERP system conversion, which was accomplished within the third quarter of 2025.
• GAAP internet loss was $1.13 billion; GAAP working loss was $0.92 billion. GAAP outcomes for fiscal 2025 embody a non-cash goodwill impairment cost of $701 million recorded within the third quarter of 2025 associated to prior acquisition accounting; the underlying enterprise delivered adjusted EBITDA of $597 million.
• GAAP internet loss margin was (41)%; GAAP working margin was (34)%; the adjusted EBITDA margin was 22%, an enchancment of 240 foundation factors.
• GAAP diluted loss per share was $16.69; adjusted diluted earnings per share have been $2.12.

Proceed studying